Clinical evaluation alone, including the measurement of cervical length and dilatation, is not sufficiently predictive of imminent delivery among patients with signs of threatened preterm labor.

Similarly, currently available biomarker tests, such as that which is based on the detection of fetal fibronectin (fFN), have extremely poor positive predictive values for imminent delivery.1

The PartoSure Test is a rapid, non-invasive strip test for the detection of placental alpha microglobulin-1 (PAMG-1) in patients presenting with signs and symptoms of preterm labor.

PartoSure’s unique features include:

  • High Positive (PPV) and Negative Predictive Value (NPV)
  • May be used shortly after vaginal exam
  • Speculum examination optional
  • Results in 5 minutes or less
  • No special equipment or training needed
  • Wide gestational age range from 20 to 37 weeks

Cervical length measurement (CL) is least accurate as a predictor of imminent spontaneous delivery in threatened preterm labor (PTL) patients when it is between 15 and 30 mm.5-7

The PartoSure test is most useful in cases where CL is between 15 and 30 mm where the predictive value of CL is lowest. While a CL-cutoff of 25 mm is often utilized, up to 1 in 8 women with a CL between 25-30 mm will deliver within the next 7 days.4

Consistent performance across studies and geographies

An average admission during which the patient is treated can cost up to 8000 €.14

The high accuracy of the PartoSure test may therefore contribute to reducing costs by:

  • Reducing the length of stay of high risk patients
  • Decreasing unnecessary admissions and acute interventions
  • Minimizing unnecessary patient transfers